NEW YORK (GenomeWeb News) – Waters today reported that its revenues in the third quarter were up 2 percent year over year, with weak pharma sales countering improved government and academic demand.

The company posted revenues of $457.3 million, up from $450 million in Q3 2012, but short of the average Wall Street estimate of $463.5 million. Foreign currency translation lowered sales growth by 2 percent, Waters said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: map of human protein interactions, mutant phenotype variability in organisms of the same species from different genetic backgrounds, and more.

Critics call the Fred Hutchinson Cancer Research Center's Gary Gilliland's prediction of cancer cures within 10 years "out of touch with reality" and "irresponsible."

Ivan Oransky discusses the need for reproducibility research at The Conversation.

The San Diego Union-Tribune posts videos from Biocom's Speaker Series with Illumina's Jay Flatley, who discusses Roche's failed hostile takeover bid.